Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Research and Markets - Botulinum Toxin Market 2015-2022 - Global Strategic Business Report 2016: Leading Players are Allergan, Ipsen, Medy-Tox, Merz Pharma, Metabiologics, Revance Therapeutics & US WorldMeds

This image opens in the lightbox

News provided by

Research and Markets

25 Oct, 2016, 21:10 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, October 25, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Botulinum Toxin - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 15 companies including many key and niche players such as

  • Allergan Plc (Ireland)
  • Ipsen Group (France)
  • Medy-Tox Inc. (South Korea)
  • Merz Pharma GmbH & Co. KGaA (Germany)
  • Metabiologics, Inc. (US)
  • Revance Therapeutics, Inc. (US)
  • US WorldMeds (US)

Key Topics Covered:

1. INDUSTRY OVERVIEW

  • Botulinum Toxin: Expanding Cosmetic & Therapeutic Applications to Propel Growth
  • Developed Regions Dominate Botulinum Toxin Market
  • Developing Markets to Drive Future Growth
  • Cosmetic BTX
  • A Promising Application Market
  • Factors Propelling the Cosmetic BT Market
  • In a Nut Shell
  • Rise in the Number of Musculoskeletal Indications
  • An Opportunity Indicator
  • Pharma Companies Keenly Eye Lucrative BT Market

2. COMPETITIVE LANDSCAPE

  • Allergan Leads the Global BTX Market
  • Botulinum Toxin Products Worldwide
  • Botox
  • The Leading Brand in Cosmetic BTX Market
  • Biosimilar BTX Variants Challenge Botox's Leadership
  • Discontinuation of PurTox Averts Competition to Botox®
  • Lack of Differentiation among Approved BTX Products
  • Comparison of Leading Neurotoxins
  • Botox, Dysport and Xeomin by Safety and Efficacy
  • Revance Therapeutics: All Hopes on Topical Botox Formulation
  • Daewoong Pharmaceutical All Set to Make a Mark on the International Scenario
  • A Review of Major BTX Products

3. MARKET TRENDS & ISSUES

  • Rising Demand for Non-Invasive Cosmetic Treatments Bodes Well for BTX Market
  • Botulinum Toxin
  • The Preferred Solution in Facial Injectables Market
  • Growing Acceptance of Cosmetic BTX Treatments Favors Market Growth
  • Rising Disposable Incomes Propel Sales
  • Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or Jubilation?
  • Urgent Need for Physician Education about Off-Label Usage
  • High Voltage Ad Campaigns Boost Patient Awareness
  • Digital Revolution to Impact Consumer Choices
  • Financing of Non-Reimbursed Healthcare: Need of the Hour
  • Combination Therapies: A Double Whammy Success

4. PRODUCT OVERVIEW

  • Botulinum Toxin: A Poison That Cures
  • Structure & Mechanism of Action
  • Disadvantages
  • Classification of Botulinum Toxin
  • Botulinum Toxin Type A
  • Historical Timeline of Botulinum Toxin: 1885-2002
  • Key Cosmetic Indications for Botulinum Toxin
  • Site of Injection and Doses of Neurotoxins used in the Treatment of Dystonias
  • Chronic Pain
  • Botox in Migraine Treatment
  • Hyperhidrosis
  • Bladder Dysfunctions
  • Spasticity
  • Other Applications
  • Side Effects
  • An Overview of Side Effects of BTX Treatment

5. RESEARCH BREAKTHROUGHS IN THE RECENT PAST

  • University of Kansas Researchers Study Botulinum ToxinA Role in Minimally Invasive Treatment of Neurogenic Bladder
  • Researchers at Baylor College of Medicine Revealed Use of Botox Injections for Treatment of Filamentary Keratitis
  • Researchers at Medical School of Hannover and Sanford-Burnham Medical Research Institute Study Effect of the Hostile Human Stomach Environment on BT
  • Investigators Prove Role of BTX A for Treatment of Achalasia
  • Researchers at University of Freiburg Conduct New Studies on Salmonella
  • Researchers at Monash University Use Botox to Resolve Asthma Wrinkles

6. PRODUCT INTRODUCTIONS/APPROVALS

  • Galderma Initiates Phase II Clinical Trial on Botulinum Toxin
  • Daewoong Unveils Nabota Botulinum Toxin-Type Formula
  • Medy-TOX Submits Patent Application for Lyophilized Botulinum Toxin
  • Botox Receives Approval for Treatment of Ankle Disability in the UK
  • Anterios Develops AI-09 Next-Generation Injectable Botulinum Product
  • Ipsen Receives Health Canada Approval for Dysport®
  • Eisai Announces Plans to Launch Nerbloc® in Japan
  • Cangene Receives FDA Approval for Botulism Antitoxin
  • Allergan Receives FDA Approval for BOTOX® for the Treatment of Crow's Feet Lines in Adults

7. RECENT INDUSTRY ACTIVITY

  • Allergan Gains Marketing Approval for BOTOX Vista® in Japan
  • Allergan Takes Over Anterios
  • FDA Approves BOTOX® for Treatment of Adult Lower Limb Spasticity
  • Revance Releases Phase 2 Trial Results of RT001 Topical Botulinum Toxin Type A Drug Candidate
  • Ipsen Collaborates with EpiVax for Developed Next-Gen Botulinum Toxins
  • Revance Begins Phase 3 Clinical Trial for Botulinum Toxin Type A Topical Gel
  • Bloomage BioTechnology and Medytox to Establish JV in China
  • Ipsen Gains FDA's sBLA Approval for Dysport®
  • Actavis Bags FDA Approval for Expanding BOTOX® Label
  • Actavis Acquires Allergan

8. FOCUS ON SELECT GLOBAL PLAYERS

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 15 (including Divisions/Subsidiaries 18)

  • The United States (6)
  • Japan (1)
  • Europe (5)
  • - France (1)
  • - Germany (1)
  • - The United Kingdom (1)
  • - Rest of Europe (2)
  • Asia-Pacific (Excluding Japan) (6)

For more information about this report visit http://www.researchandmarkets.com/research/qcctbl/botulinum_toxin

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.